Company news

uniQure N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

June 30, 2024

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

June 2, 2024

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 6, 2024

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

February 27, 2024

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

December 18, 2023

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 7, 2023

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

November 28, 2023

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 6, 2023

CSL and uniQure Win 2023 Prix Galien USA Award

October 26, 2023

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

October 23, 2023

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

October 4, 2023

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

September 4, 2023

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

July 31, 2023

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

June 25, 2023

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

June 20, 2023

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

June 19, 2023

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

June 19, 2023

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

May 14, 2023

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 8, 2023

uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2023

uniQure to Participate in Multiple Upcoming Industry Conferences in March

March 1, 2023

uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

February 26, 2023

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

February 22, 2023

uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

February 20, 2023

uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

January 30, 2023

uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

December 15, 2022

uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

November 28, 2022

uniQure announces FDA approval of first gene therapy for adults with hemophilia B

November 21, 2022

uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022

November 16, 2022

uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 1, 2022

uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

October 10, 2022

uniQure to Participate in Upcoming Industry Conferences in October

October 2, 2022

uniQure to Participate in Upcoming Industry Conferences in September

September 5, 2022

uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 7, 2022

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

June 22, 2022

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

May 23, 2022

uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2022

uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 1, 2022

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B

March 27, 2022

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

March 20, 2022

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

February 24, 2022

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

February 6, 2022

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022

February 3, 2022

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

December 15, 2021

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

December 8, 2021

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

November 1, 2021

uniQure to Participate in Upcoming Industry Conferences in November

October 31, 2021

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

October 24, 2021

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

October 20, 2021

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

October 18, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.